FGF19 promotes progression of prostate cancer

Prostate

Volumn 75, Issue 10, 2015, Pages 1092-1101

  Nagamatsu, Hirotaka ^a   Teishima, Jun ^a   Goto, Keisuke ^a   Shikuma, Hiroyuki ^a   Kitano, Hiroyuki ^a   Shoji, Koichi ^a   Inoue, Shogo ^a   Matsubara, Akio ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

endocrine; FGF19; prostate cancer

Indexed keywords

ANDROGEN; CASPASE 3; FIBROBLAST GROWTH FACTOR 19; NERVE CELL ADHESION MOLECULE; PROSTATE SPECIFIC ANTIGEN; UVOMORULIN; CADHERIN; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; BIOCHEMICAL RECURRENCE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BODY MASS; CANCER GROWTH; CANCER PROGNOSIS; CELL PROLIFERATION; CELL VIABILITY; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LNCAP CELL LINE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MTT ASSAY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; STAINING; WESTERN BLOTTING; BLOOD; CHEMISTRY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTOR; TUMOR CELL LINE; TUMOR RECURRENCE;

AGED; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLAST GROWTH FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84929024583     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22994     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J, Ward E, Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Freedland SJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Trock B, Aronson WJ, Search Database Study Group, Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol 2004; 172 (2): 520-524.
3. Freedland SJ, Bañez LL, Sun LL, Fitzsimons NJ, Moul JW, Obese men have higher-grade and larger tumors: An analysis of the duke prostate center database. Prostate Cancer Prostatic Dis 2009; 12 (3): 259-263.
4. Kwabi-Addo B, Ozen M, Ittmann M, The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004; 11 (4): 709-724.
5. Teishima J, Shoji K, Hayashi T, Miyamoto K, Ohara S, Matsubara A, Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence. Prostate Cancer Prostatic Dis 2012; 15 (1): 8-14.
6. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, Vandlen R, Simmons L, Foster J, Stephan JP, Tsai SP, Stewart TA, Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145 (6): 2594-2603.
7. Choi M, Moschetta A, Bookout AL, Peng L, Umetani M, Holmstrom SR, Suino-Powell K, Xu HE, Richardson JA, Gerard RD, Mangelsdorf DJ, Kliewer SA, Identification of a hormonal basis for gallbladder filling. Nat Med 2006; 12 (11): 1253-1255 [Epub 2006 October 29].
8. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB, FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115 (6): 1627-1635.
9. Hori M, Shimizu Y, Fukumoto S, Minireview: Fibroblast growth factor 23 in phosphate homeostasis and bone metabolism. Endocrinology 2011; 152 (1): 4-10.
10. Kurosu H, Kuro OM, The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 2009; 299 (1): 72-78.
11. Feng S, Dakhova O, Creighton CJ, Ittmann M, Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res 2013; 73 (8): 2551-2562.
12. Ohara S, Oue N, Matsubara A, Mita K, Hasegawa Y, Hayashi T, Usui T, Amatya VJ, Takeshima Y, Kuniyasu H, Yasui W, Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer. Cancer Sci 2008; 99 (8): 1570-1577.
13. Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, Pham TA, Dillard-Telm L, Tsai SP, Stephan JP, Stinson J, Stewart T, French DM, A mouse model of hepatocellular carcinoma: Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 160 (6): 2295-2307.
14. Desnoyers LR, Pai R, Ferrando RE, Hötzel K, Le T, Ross J, Carano R, D'Souza A, Qing J, Mohtashemi I, Ashkenazi A, French DM, Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008; 27 (1): 85-97.
15. Pai R, Dunlap D, Qing J, Mohtashemi I, Hotzel K, French DM, Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res 2008; 68 (13): 5086-5095.
16. Reiche M, Bachmann A, Lössner U, Blüher M, Stumvoll M, Fasshauer M, Fibroblast growth factor 19 serum levels: Relation to renal function and metabolic parameters. Horm Metab Res 2010; 42 (3): 178-181.
17. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D, Stewart TA, Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143 (5): 1741-1747.
18. Lundåsen T, Gälman C, Angelin B, Rudling M, Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260 (6): 530-536.
19. Stejskal D, Karpísek M, Hanulová Z, Stejskal P, Fibroblast growth factor-19: Development, analytical characterization and clinical evaluation of a new ELISA test. Scand J Clin Lab Invest 2008; 68 (6): 501-507.
20. Giri D, Ropiquet F, Ittmann M, Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999; 5 (5): 1063-1071.
21. Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN, Leung HY, Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005; 92 (2): 320-327.
22. Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ, Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007; 213 (1): 82-90.
23. Murphy T, Darby S, Mathers ME, Gnanapragasam VJ, Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol 2010; 220 (4): 452-460.